GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Teyi Pharmaceutical Group Co 002728.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

9.33

+3.44%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Teyi Pharmaceutical Group Co

Its shares trade on Shenzhen under the ticker 002728.SZ. It has been listed since 31 July 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥915.7m and net income of CN¥81.7m. At that date it held total assets of CN¥2.31bn and shareholders' equity of CN¥1.82bn.

Teyi Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and pharmaceutical health industry. The company is headquartered in Jiangmen, Guangdong. The company went IPO on 2014-07-31. The firm primarily provides Chinese traditional patent medicines, including cough arresting and phlegm removing medicine series, kidney reinforcing medicine series and anti-infection medicine series, among others. The firm's products mainly include tablets, granules, medicinal tea, syrup, decocted extracts, capsules, powder, ointment, cream, as well as oral solutions, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
31 Jul 2014
Employees
1,243
Website
tczy.com.cn ↗

Leadership

Pay as last reported

  • Mr. Ronghuang XuExecutive Chairman of the Board, General Manager(Manager), since 2025
  • Mr. Xiliang ChenChief Financial Officer, Deputy General Manager, Director, since 2009CN¥459,300
  • Mr. Weicheng WuDeputy General Manager
  • Mr. Rongjun XuDeputy General Manager
  • Mr. Wenge YanDeputy General Manager
  • Mr. Yongzhao ZhangDeputy General ManagerCN¥213,300
  • Ms. Zilan XuSecretary of the Board
  • Mr. Beijing LuDirectorCN¥72,000
  • Ms. Ruqing YaoStaff Elected Director
  • Mr. Hanqi LaiIndependent Director
  • Ms. Xiaobo ZhaoIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 1243 full-time employees
  • Headquartered in Jiangmen, Guangdong
  • Provides Chinese traditional patent medicines including cough arresting and phlegm removing medicine series

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No financial data provided for analysis
  • No market share or competitive position details

Opportunities

  • Expansion in pharmaceutical health industry
  • Growth potential in Chinese traditional medicine market
  • Potential for product line diversification

Threats

  • No specific threats mentioned in the provided information
  • No competitive landscape details provided
  • No regulatory or market risk factors identified

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.